Event Details

Aimmune at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2020

June 08, 2020

Supporting Materials

PALISADE Follow-On Study (ARC004): Longer-Term Outcomes With AR101 Oral Immunotherapy for Peanut Allergy 465.6 KB

Treatment Satisfaction With AR101 Oral Immunotherapy for Peanut Allergy in a European Paediatric Population 490.7 KB

Peanut Allergy Impact on PRoductIvity and QUAlity of Life (PAPRIQUA): The Psychosocial Impact of Peanut Allergy in Children and Caregivers 194.1 KB

Event Details

ShareThis Copy and Paste

Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT

Webcast Presentation

Help

Click here for webcast

— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...